Of note, there are more clinical entities in which studies reported that a dysregulation of PRL and of the PRL/vasoinhibin axis might play a role, for example, breast and prostate cancer (71–75), preeclampsia and eclampsia (67, 76, 77), pregnancy-induced hypertension (78), pulmonary artery hypertension (79), retinopathy of prematurity (28), and rheumatoid arthritis (80). Here, PRL is linked to prostate carcinoma.